<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Olivia Des Vinca Albahana Napitupulu</style></author><author><style face="normal" font="default" size="100%">Gusbakti Rusip</style></author><author><style face="normal" font="default" size="100%">Maya Sari Mutia</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Therapeutic Effects of Combined Zinc and α-Tocopherol Administration in a Rat Model of Staphylococcus aureus-Induced Sepsis</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">CRP</style></keyword><keyword><style  face="normal" font="default" size="100%">Histopathology</style></keyword><keyword><style  face="normal" font="default" size="100%">IL-6</style></keyword><keyword><style  face="normal" font="default" size="100%">Oxidative stress</style></keyword><keyword><style  face="normal" font="default" size="100%">Sepsis</style></keyword><keyword><style  face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style  face="normal" font="default" size="100%">TNF-α</style></keyword><keyword><style  face="normal" font="default" size="100%">Vitamin E</style></keyword><keyword><style  face="normal" font="default" size="100%">zinc</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2025</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">275-283</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Sepsis induces systemic inflammation through excessive production of proinflammatory cytokines, leading to oxidative stress, tissue damage, and multiorgan dysfunction. This study aimed to evaluate the synergistic effects of combined zinc and vitamin E (α-tocopherol) supplementation on inflammatory and biochemical parameters in&lt;em&gt; Staphylococcus aureus&lt;/em&gt;-induced sepsis in male Wistar rats. Thirty rats were divided into six groups: (1) normal control, (2) Placebo control (sepsis without therapy), (3) positive control (levofloxacin 45 mg/kg BW + zinc 0.9 mg/kg BW + vitamin E 250 mg/kg BW), and (4–6) treatment groups receiving combined zinc (0.9, 1.8, and 2.7 mg/kg BW) with vitamin E (250 mg/kg BW). Sepsis was induced intraperitoneally, followed by treatment according to group. On day 9, serum levels of TNF-α, IL-6, CRP, AST, ALT, urea, creatinine, and albumin were analyzed, while lung and kidney, were examined histologically. The combination of zinc and vitamin E significantly decreased TNF-α, IL-6, and CRP levels while improving biochemical parameters and increasing serum albumin compared to the untreated group (p ≤ 0.05). The highest efficacy was observed with zinc 2.7 mg/kg BW and vitamin E 250 mg/kg BW, which showed over 50% reduction in tissue damage, reduced inflammatory cell infiltration and interstitial hemorrhage in lung tissue, and improved hepatic cellular regeneration. These findings suggest that zinc and vitamin E exert synergistic anti-inflammatory and antioxidative effects, indicating their potential as adjuvant therapy in sepsis management.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">275</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Olivia Des Vinca Albahana Napitupulu&lt;sup&gt;1&lt;/sup&gt;, Gusbakti Rusip&lt;sup&gt;2*&lt;/sup&gt;, Maya Sari Mutia&lt;sup&gt;3&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Program, Faculty of Medicine, Universitas Prima Indonesia, Medan, INDONESIA&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Family Medicine, Faculty of Medicine, Universitas Prima Indonesia, Medan, INDONESIA&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Deparment of Histology, Faculty of Medicine, Universitas Prima Indonesia, Medan, INDONESIA&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ummi Nafi’atil Ilmi</style></author><author><style face="normal" font="default" size="100%">IGAA Putri Sri Rejeki</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Multi Bacterial Infection in Immunocompromised Patient</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Immunocompromised</style></keyword><keyword><style  face="normal" font="default" size="100%">Multidrug-resistant bacteria (MDR)</style></keyword><keyword><style  face="normal" font="default" size="100%">Sepsis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">402-406</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Infection is a major cause of morbidity and mortality in immunocompromised cancer patients due to chemotherapy, radiotherapy, or anti-inflammatory therapy. Approximately 0.9%-39% of cancer patients with febrile non neutropenia has bacteremia and about 7.3% of cancer patients hospitalized have positive bacterial blood cultures. Multi-bacterial infection with Multi Drug Resistant (MDR) in immunocompromised cancer patients complicates therapy and is often fatal. A 6 years old boy diagnosed with left orbital tumor intracranial infiltration. Physical examination: lump in the left eye ± 8 x 10 cm, solid, reddish in color, there was a wound on the left eye ± 12 x 10 cm; Temperature 39&lt;sup&gt;0&lt;/sup&gt;C. Hematology examination Hb 10.3 g / dL; PLT 156 x103 / uL; WBC 28.92 x103 / uL. Blood culture results: Methicillin Resistant&lt;em&gt; Staphylococcus aureus&lt;/em&gt; (MRSA) resistant to Gentamicin, Amoxicillin Clavulanic Acid, Ampicillin, Penicillin G, Oxacillin and&lt;em&gt; Enterococcus faecium &lt;/em&gt;resistant to Gentamicin, Ampicillin, Cotrimoxazole, Trimetoprim, Erythromycin, and Clindamycin. Results of pus culture from the left eye wound was &lt;em&gt;Staphylococcus intermedius &lt;/em&gt;resistant to Gentamicin, Amoxicillin Clavulanic Acid, Ampicillin, Penicillin G, Oxacillin, Chloramphenicol, Ciprofloxacin. Based on the results of blood and pus culture, all bacterial isolates included multidrug-resistant organisms (MDRO). Multidrug resistant organisms are microorganisms, especially bacteria that are resistant to at least 1 antibiotic of three or more categories. Cancer patients are susceptible to infection with multi-drug resistant bacteria because of their decreased immune system, especially after undergoing chemotherapy. Appropriate antibiotic treatment determines patient morbidity and mortality. Infection due to multi-bacteria accompanied by multi-drug resistance in immunocompromised patients is a condition that has to be treated immediately since the onset of the disease to reduce morbidity and mortality.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Research Article </style></work-type><accession-num><style face="normal" font="default" size="100%">22</style></accession-num><section><style face="normal" font="default" size="100%">402</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Ummi Nafi’atil Ilmi&lt;sup&gt;1&lt;/sup&gt;, IGAA Putri Sri Rejeki&lt;sup&gt;2&lt;/sup&gt;,* &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Clinical Pathology Specialization Program, Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Dr Soetomo General Academic Hospital Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Dr Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>